Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.65 |
| ▸ | NPC1 | O15118 | 8/20 | 0.55 |
| ▸ | RAB9A | P51151 | 8/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.47 |
| ▸ | TP53 | P04637 | 7/20 | 0.47 |
| ▸ | PKM | P14618 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14394942 | 0.85 | GRM5 (0.56) | GRM5NPC1RAB9AKCNH2SMN1; SMN2 | |
| SCHEMBL4188207 | 0.85 | GRM5 (0.69) | GRM5NPC1RAB9AKCNH2SMN1; SMN2 | |
| SCHEMBL4198164 | 0.84 | GRM5 (0.57) | GRM5NPC1RAB9AKCNH2SMN1; SMN2 | |
| SCHEMBL4192819 | 0.82 | TP53 (0.57) | GRM5NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4195255 | 0.82 | GRM5 (0.76) | GRM5NPC1RAB9AKCNH2SMN1; SMN2 | |
| SCHEMBL4179004 | 0.82 | SMN1; SMN2 (0.54) | GRM5NPC1RAB9AKCNH2SMN1; SMN2 | |
| SCHEMBL5228245 | 0.81 | GRM5 (0.61) | GRM5NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4199939 | 0.81 | GRM5 (0.63) | GRM5NPC1RAB9AKCNH2SMN1; SMN2 | |
| SCHEMBL5226204 | 0.80 | GRM5 (0.60) | GRM5NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4197929 | 0.79 | GRM5 (1.00) | GRM5NPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1896011-A1 | NEW USE | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | claimed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| WO-2007001973-A1 | NEW USE | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | WO | claimed |
| WO-2005060971-A1 | TREATMENT OF REFLUX-RELATED DISEASES | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | claimed |
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1896011-A1 | NEW USE | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| CN-1332959-C | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2007-08-22 | — | — | CN | disclosed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| WO-2007001973-A1 | NEW USE | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | WO | disclosed |
| CN-1853630-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1649865-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005060971-A1 | TREATMENT OF REFLUX-RELATED DISEASES | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885NPC1 941/4885RAB9A 1813/4885 |
| US-20090054491-A1 | Use | FABP6, SLC10A2, GPR119 | GRM5 582/4885NPC1 463/4885RAB9A 3862/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885NPC1 941/4885RAB9A 1813/4885 |
| US-20070010553-A1 | New use | GRM5, GRM3, GRM1 | GRM5 1/4885NPC1 1385/4885RAB9A 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.